688076 ST诺泰
交易中 06-05 10:03:12
资讯
新帖
简况
ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段
证券之星 · 06-03 16:27
ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段
ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系
证券之星 · 06-03 16:27
ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系
每周股票复盘：ST诺泰（688076）2025年年度股东会顺利召开
证券之星 · 05-31
每周股票复盘：ST诺泰（688076）2025年年度股东会顺利召开
股市必读：ST诺泰（688076）今年截至5月28日累计跌幅已超25%
证券之星 · 05-29
股市必读：ST诺泰（688076）今年截至5月28日累计跌幅已超25%
每周股票复盘：ST诺泰（688076）2025年净利3.32亿拟每股分红0.35元
证券之星 · 05-24
每周股票复盘：ST诺泰（688076）2025年净利3.32亿拟每股分红0.35元
ST诺泰（688076）披露控股股东、实际控制人续签一致行动协议公告，5月21日股价下跌1.23%
证券之星 · 05-21
ST诺泰（688076）披露控股股东、实际控制人续签一致行动协议公告，5月21日股价下跌1.23%
ST诺泰（688076）披露2025年年度股东会会议资料，5月18日股价下跌0.99%
证券之星 · 05-18
ST诺泰（688076）披露2025年年度股东会会议资料，5月18日股价下跌0.99%
每周股票复盘：ST诺泰（688076）2026Q1营收略降扣非净利下滑17.78%
证券之星 · 05-17
每周股票复盘：ST诺泰（688076）2026Q1营收略降扣非净利下滑17.78%
股市必读：ST诺泰（688076）5月14日披露最新机构调研信息
证券之星 · 05-15
股市必读：ST诺泰（688076）5月14日披露最新机构调研信息
每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%
证券之星 · 05-10
每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%
ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%
证券之星 · 05-08
ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%
ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%
证券之星 · 04-30
ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%
图解ST诺泰年报：第四季度单季净利润同比下降307.09%
证券之星 · 04-30
图解ST诺泰年报：第四季度单季净利润同比下降307.09%
每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿
证券之星 · 04-12
每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿
ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%
中金财经 · 04-07
ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%
股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%
证券之星 · 03-24
股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%
每周股票复盘：ST诺泰（688076）2025年净利降19.14%
证券之星 · 03-01
每周股票复盘：ST诺泰（688076）2025年净利降19.14%
ST诺泰发布2025年度业绩快报，盈利3.27亿元
证券之星 · 02-27
ST诺泰发布2025年度业绩快报，盈利3.27亿元
每周股票复盘：ST诺泰（688076）子公司通过药品GMP检查
证券之星 · 02-08
每周股票复盘：ST诺泰（688076）子公司通过药品GMP检查
ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查
证券之星 · 02-03
ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查
加载更多
公司概况
公司名称：
江苏诺泰澳赛诺生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2021-05-20
主营业务：
江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是定制类产品、技术服务、自主选择产品。
发行价格：
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"ST诺泰","latestPrice":28.74,"timestamp":1780624992000,"preClose":28.7,"halted":0,"volume":442946,"delay":0,"changeRate":0.0014,"floatShares":316000000,"shares":316000000,"eps":0.9786,"marketStatus":"交易中","change":0.04,"latestTime":"06-05 10:03:12","open":29.29,"high":29.29,"low":28.68,"amount":12840500,"amplitude":0.0213,"askPrice":28.75,"askSize":20,"bidPrice":28.7,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.9786,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1780630200000},"marketStatusCode":2,"adr":0,"adjPreClose":28.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":30.14,"lowLimit":27.26,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":316051897,"isCdr":false,"pbRate":2.91,"roa":"--","peRate":29.368486,"roe":"4.24%","epsLYR":1.06,"committee":-0.237624,"marketValue":9083000000,"turnoverRate":0.0014,"status":0,"floatMarketCap":9083000000},"requestUrl":"/m/hq/s/688076","defaultTab":"news","newsList":[{"id":"2640972060","title":"ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640972060?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475256,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有英克司兰原料药的技术，建议公司开发相当于英克司兰的长效降脂药物品种，在小核酸方向主攻研发创新药，加大研发。祝公司越来越好。ST诺泰回复：尊敬的投资者您好，公司自主研发的英克司兰注射液目前处于小试阶段，具体您可查阅公司2025年年度报告-在研项目情况，感谢您的关注与建议！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640722199","title":"ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2640722199","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640722199?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475250,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好 近日看到信达与辉瑞签订超100亿美元的肿瘤药物研发合同，我想请问诺泰生物何时能具备与国际大厂签订药物研发计划的能力？ST诺泰回复：尊敬的投资者您好，公司已与Incyte、Gilead等知名创新药企建立了稳固的合作关系，公司会在定期报告中披露已签署重要订单情况。此外，公司如签订达到《上海证券交易所科创板股票上市规则》中规定的重大合同披露标准的订单合同，会及时履行信息披露义务，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239","BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604120","title":"每周股票复盘：ST诺泰（688076）2025年年度股东会顺利召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604120?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:39","pubTimestamp":1780169949,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，ST诺泰报收于29.84元，较上周的30.53元下跌2.26%。本周关注点公司公告汇总：ST诺泰2025年年度股东会于2026年5月26日召开，审议通过多项议案，表决程序合法有效。江苏诺泰澳赛诺生物制药股份有限公司于2026年5月26日召开2025年年度股东会，会议由董事会召集，董事长童梓权主持，采用现场与网络投票结合方式表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639618903","title":"股市必读：ST诺泰（688076）今年截至5月28日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639618903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639618903?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:10","pubTimestamp":1779991824,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，ST诺泰报收于29.69元，下跌0.13%，换手率0.58%，成交量1.83万手，成交额5388.66万元。当日关注点来自交易信息汇总：ST诺泰股价连续5日下跌，2026年累计跌幅达26.58%。交易信息汇总股价提醒5月28日ST诺泰收盘报29.69元，跌0.13%，当日成交182.77万元。前10个交易日中，主力资金累计净流出8579.97万元，股价累计下跌5.52%；融资余额累计减少2458.33万元，融券余量累计增加1300股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637375857","title":"每周股票复盘：ST诺泰（688076）2025年净利3.32亿拟每股分红0.35元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637375857","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637375857?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:18","pubTimestamp":1779563892,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，ST诺泰报收于30.53元，较上周的31.29元下跌2.43%。本周，ST诺泰5月19日盘中最高价报31.66元。2025年公司实现营业收入19.43亿元，同比增长19.57%；归属于母公司所有者的净利润3.32亿元。ST诺泰：关于公司控股股东、实际控制人续签一致行动协议的公告江苏诺泰澳赛诺生物制药股份有限公司控股股东、实际控制人赵德毅、赵德中于2026年5月20日续签《一致行动协议》，新协议有效期自签署之日起一年，至2027年5月19日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138422","title":"ST诺泰（688076）披露控股股东、实际控制人续签一致行动协议公告，5月21日股价下跌1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138422","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138422?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:09","pubTimestamp":1779358157,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，ST诺泰报收于30.55元，较前一交易日下跌1.23%，最新总市值为96.55亿元。公司于近日披露《关于公司控股股东、实际控制人续签一致行动协议的公告》。公告显示，江苏诺泰澳赛诺生物制药股份有限公司控股股东、实际控制人赵德毅、赵德中于2026年5月20日续签《一致行动协议》，新协议有效期自签署之日起一年，至2027年5月19日止。本次续签不影响公司实际控制权，控制权未发生变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636074510","title":"ST诺泰（688076）披露2025年年度股东会会议资料，5月18日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636074510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636074510?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:24","pubTimestamp":1779114263,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，ST诺泰报收于30.98元，较前一交易日下跌0.99%，最新总市值为97.91亿元。该股当日开盘31.37元，最高31.37元，最低30.75元，成交额达5730.42万元，换手率为0.59%。近日，ST诺泰发布《2025年年度股东会会议资料》。2025年公司实现营业收入19.43亿元，同比增长19.57%；归属于母公司所有者的净利润3.32亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636064596","title":"每周股票复盘：ST诺泰（688076）2026Q1营收略降扣非净利下滑17.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064596","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636064596?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:12","pubTimestamp":1778958731,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，ST诺泰报收于31.29元，较上周的32.1元下跌2.52%。本周，ST诺泰5月12日盘中最高价报33.28元。本周关注点来自业绩披露要点：2025年归母净利润下滑17.8%，主要受资产减值、证监会罚款及财务费用上升影响。2026年Q1营收同比略降主要因流感季节性影响，抗病毒制剂销售额下降；部分产品受行业价格波动影响毛利率下滑，拖累净利润。2026Q1营收下降系流感季节性波动所致，非价跌量升；抗病毒制剂销售收入同比下降为主要原因。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635574787","title":"股市必读：ST诺泰（688076）5月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635574787?lang=zh_cn&edition=full","pubTime":"2026-05-15 02:02","pubTimestamp":1778781738,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，ST诺泰报收于31.45元，下跌2.39%，换手率0.96%，成交量3.04万手，成交额9637.67万元。来自机构调研要点：司美格鲁肽、替尔泊肽、利拉鲁肽三个GLP-1原料药2025年出货量同比大幅增长。2026年Q1营收同比下降主要因流感季节性影响，抗病毒制剂产品销售下滑；部分产品受行业价格波动影响，毛利率同比下降。公司力争2026年度营业收入较上年保持稳定增长，该预算不代表盈利预测，亦不构成对股东的承诺，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634411497","title":"每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634411497","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634411497?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:44","pubTimestamp":1778348653,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，ST诺泰报收于32.1元，较上周的29.73元上涨7.97%。本周，ST诺泰5月8日盘中最高价报32.2元。本周关注点公司公告汇总：公司被证监会罚款4,740万元，多名高管被警告并处罚。公司公告汇总南京证券作为江苏诺泰澳赛诺生物制药股份有限公司的保荐机构，出具2025年度持续督导报告书。2025年公司营业收入同比增长19.57%，净利润同比下降17.80%，研发投入占比上升至23.37%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633034452","title":"ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633034452","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633034452?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:12","pubTimestamp":1778249543,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，ST诺泰报收于32.1元，较前一交易日上涨7.18%，最新总市值为101.45亿元。该股当日开盘30.11元，最高32.2元，最低29.95元，成交额达2.15亿元，换手率为2.16%。近日，南京证券股份有限公司作为江苏诺泰澳赛诺生物制药股份有限公司的保荐机构，发布《关于江苏诺泰澳赛诺生物制药股份有限公司2025年度持续督导报告书》。保荐机构督促公司整改，强化公司治理与内部控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800043603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631687610","title":"ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631687610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631687610?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:07","pubTimestamp":1777543635,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，ST诺泰报收于29.73元，较前一交易日上涨1.75%，最新总市值为93.96亿元。该股当日开盘29.59元，最高29.99元，最低29.58元，成交额达6137.48万元，换手率为0.65%。公司于2026年4月30日披露《2025年年度报告》。报告显示，2025年公司总资产6,740,348,583.14元，归属于上市公司股东的净资产2,985,566,515.25元，营业收入1,942,799,144.82元，利润总额360,489,776.54元，归属于上市公司股东的净利润332,418,681.18元，归属于上市公司股东的扣除非经常性损益的净利润366,170,169.99元，经营活动产生的现金流量净额681,242,898.86元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000058548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631442475","title":"图解ST诺泰年报：第四季度单季净利润同比下降307.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631442475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631442475?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:55","pubTimestamp":1777481715,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰2025年年报显示，当年度公司主营收入19.43亿元，同比上升19.57%；归母净利润3.32亿元，同比下降17.8%；扣非净利润3.66亿元，同比下降10.21%；其中2025年第四季度，公司单季度主营收入4.16亿元，同比上升11.56%；单季度归母净利润-1.12亿元，同比下降307.09%；单季度扣非净利润-7081.72万元，同比下降233.27%；负债率55.47%，投资收益202.56万元，财务费用5781.34万元，毛利率62.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000002938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626212471","title":"每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2626212471","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626212471?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:28","pubTimestamp":1775928489,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，ST诺泰报收于30.7元，较上周的29.02元上涨5.79%。本周，ST诺泰4月10日盘中最高价报31.1元。本周关注点业绩披露要点：ST诺泰预计2026年一季度扣非及归属净利润均为1.2亿元至1.4亿元。公司公告汇总：ST诺泰称一季度净利润同比减少8.27%至21.37%，主因部分产品毛利率下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625374499","title":"ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625374499","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625374499?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:37","pubTimestamp":1775561822,"startTime":"0","endTime":"0","summary":"格隆汇4月7日丨ST诺泰(688076.SH)发布一季度业绩预告，预计一季度归属于上市公司股东的净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%；预计一季度归属于上市公司股东的扣除非经常性损益的净利润为1.20亿元—1.40亿元，同比预减7.65%—20.84%，报告期内，公司部分销售产品受行业价格波动影响，毛利率水平同比下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260407/32128790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089903","title":"股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621089903?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:19","pubTimestamp":1774293592,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，ST诺泰报收于28.61元，下跌5.58%，换手率1.29%，成交量4.07万手，成交额1.19亿元。来自交易信息汇总：该股当年累计跌幅达23.57%，前10个交易日主力资金累计净流出1.3亿元。交易信息汇总股价提醒3月23日ST诺泰收盘报28.61元，跌5.58%，当日成交407.11万元。根据收盘数据统计，该股已连续4日下跌，当年累计跌幅23.57%。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843846","title":"每周股票复盘：ST诺泰（688076）2025年净利降19.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843846","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843846?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:50","pubTimestamp":1772301020,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，ST诺泰报收于32.46元，较上周的33.78元下跌3.91%。本周关注点业绩披露要点：ST诺泰2025年归属净利润盈利3.27亿元，同比下降19.14%。本次计提导致公司2025年度合并报表利润总额减少9,189.23万元，最终数据以年度审计结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614858290","title":"ST诺泰发布2025年度业绩快报，盈利3.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858290","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614858290?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:10","pubTimestamp":1772194246,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利3.27亿元，同比减少19.14%。2025 年末公司股本较年初增加 43.80%，主要系本年度资本公积转增股本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700037713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609525264","title":"每周股票复盘：ST诺泰（688076）子公司通过药品GMP检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525264","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525264?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:22","pubTimestamp":1770488533,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，ST诺泰报收于34.8元，较上周的36.19元下跌3.84%。本周，ST诺泰2月5日盘中最高价报36.0元。本周关注点公司公告汇总：全资子公司杭州澳赛诺建德工厂奥格特韦钠原料药生产线通过药品GMP符合性检查。江苏诺泰澳赛诺生物制药股份有限公司全资子公司杭州澳赛诺生物科技有限公司近日收到浙江省药品监督管理局签发的《药品GMP符合性检查告知书》，其奥格特韦钠原料药生产线通过GMP符合性检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608293824","title":"ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2608293824","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608293824?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:00","pubTimestamp":1770112846,"startTime":"0","endTime":"0","summary":"ST诺泰(688076.SH)公告称，公司全资子公司杭州澳赛诺生物科技有限公司奥格特韦钠原料药正式通过GMP符合性检查，检查范围及相关车间、生产线包括原料药（奥格特韦钠）的一车间、六车间、九车间以及B原料药生产线。这表明公司具备领先的生产及质量管理体系，对公司持续开拓创新药原料药客户具有积极意义。但产品生产、销售受多种因素影响，对近期业绩和财务数据的影响存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300031643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780624998441,"stockEarnings":[{"period":"1week","weight":-0.0333},{"period":"1month","weight":-0.0346},{"period":"3month","weight":-0.1489},{"period":"6month","weight":-0.2316},{"period":"1year","weight":-0.1857},{"period":"ytd","weight":-0.2387}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0161},{"period":"6month","weight":0.0397},{"period":"1year","weight":0.2019},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15016人(较上一季度减少1.48%)","perCapita":"21047股","listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","registeredCapital":"31605万元","survey":" 江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是定制类产品、技术服务、自主选择产品。","listedPrice":15.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST诺泰,688076,ST诺泰股票,ST诺泰股票老虎,ST诺泰股票老虎国际,ST诺泰行情,ST诺泰股票行情,ST诺泰股价,ST诺泰股市,ST诺泰股票价格,ST诺泰股票交易,ST诺泰股票购买,ST诺泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}